The United States government will begin investigating the cause behind persistent shortages of generic drugs that are severely endangering patient lives.
First-line treatment with LTRA followed by CHOP produced a 100% complete response rate in DLBCL patients who completed both regimens. First-line treatment with LTRA followed by CHOP produced a 100% complete response rate in DLBCL patients who completed both regimens.
The use of tafasitamab-cxix, lenalidomide, rituximab, and acalabrutinib in the first-line setting induced high responses in patients with newly diagnosed diffuse large B-cell lymphoma, with responders deriving benefit from subsequent treatment with cyclophosphamide, doxorubicin, vincristine, and prednisolone.
This Week in Washington: House Energy and Commerce Committee markup includes 19 healthcare bills; Senate HELP Committee to mark up SUPPORT Act Reauthorization and three other bills;.